575 related articles for article (PubMed ID: 18723564)
1. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
[TBL] [Abstract][Full Text] [Related]
2. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
Halvorsen EH; Pollmann S; Gilboe IM; van der Heijde D; Landewé R; Ødegård S; Kvien TK; Molberg Ø
Ann Rheum Dis; 2008 Mar; 67(3):414-7. PubMed ID: 18006540
[TBL] [Abstract][Full Text] [Related]
4. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
Pollmann S; Stensland M; Halvorsen EH; Sollid LM; Kvien TK; Fleckenstein B; Molberg O
Rheumatol Int; 2012 May; 32(5):1271-6. PubMed ID: 21267570
[TBL] [Abstract][Full Text] [Related]
5. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
7. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
[TBL] [Abstract][Full Text] [Related]
8. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
Naredo E; Möller I; Cruz A; Carmona L; Garrido J
Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
[TBL] [Abstract][Full Text] [Related]
9. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
10. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
11. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
13. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
14. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
15. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
16. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
Rheumatol Int; 2010 Feb; 30(4):451-4. PubMed ID: 19506882
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study.
Ellegaard K; Christensen R; Torp-Pedersen S; Terslev L; Holm CC; Kønig MJ; Jensen PS; Danneskiold-Samsøe B; Bliddal H
Rheumatology (Oxford); 2011 Mar; 50(3):506-12. PubMed ID: 21071479
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
[TBL] [Abstract][Full Text] [Related]
19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
20. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]